Navigation Links
Revotar Reports First Positive Clinical Results From Phase IIa Study in COPD
Date:10/31/2007

HENNIGSDORF and BERLIN, Germany, October 31 /PRNewswire/ -- Revotar Biopharmaceuticals AG., today announced first positive results from an investigator driven open labelled Phase IIa pilot study in 14 patients with stable COPD stage 0 to II (GOLD criteria) inhaling 70 mg of Bimosiamose twice a day. The study was conducted at the Charite - Medical School Charite Berlin, Prof. Witt and the Respiratory Institute Wiesbaden, Dr. Beeh. The results were presented during the recent European Respiratory Society Meeting in Stockholm in September.

"Despite of the short treatment period we were surprised to see that analysis of induced sputum prior to and after Bimosiamose treatment of 9 days showed that both relative and absolute lymphocytes count decreased significantly. In addition, sputum IL-8 was significantly decreased. The latter is supposed to correlate with the severity of the disease," commented Prof. Dr. Meyer-Sabellek, clinical advisor to Revotar and previously SVP Research&Development at AstraZeneca, Germany. "Inhalation of Bimosiamose twice daily for up to 9 days was well tolerated and safe in patients. This targeted therapy provides the potential to prevent the further progression of inflammatory components in COPD and should be evaluated further in larger clinical trials," added Prof. Dr. Witt from the Charite and the Principal Investigator of the study.

About COPD

Chronic Obstructive Pulmonary Disease (COPD) comprises many serious conditions affecting the lung. More than 30 million people are living with COPD worldwide. COPD is the fourth leading cause of death and is responsible for more than 120,000 deaths a year in the US and Western Europe alone. The disease costs the US healthcare system US$40 billion per year.

About Revotar Biopharmaceutical AG

Revotar develops innovative anti-inflammatory drugs for inflammatory indications such as psoriasis, chronic obstructive pulmonary disease (COPD) and acute lung injury (ALI). Bim
'/>"/>

SOURCE Revotar Biopharmaceutics AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Seoul Semiconductor (CEO: Chung-hoon Lee, ... on May 28th announced that it will increase ... its high efficient and high reliable LED product ... Seoul Semiconductor has developed efficient and reliable LED ... supplied LEDs for headlamps to global auto makers. ...
(Date:5/28/2015)... , May 28, 2015  Quest Diagnostics Incorporated (NYSE: ... information services, announced that it is scheduled to speak ... York.  Steve Rusckowski , the company,s President and ... point strategy.  The presentation is scheduled for Tuesday, June ... The presentation will be webcast live during the conference ...
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/6cg3zw/cell_therapy ) has ... "Cell Therapy - Technologies, Markets and Companies" ... describes and evaluates cell therapy technologies and methods, ... role in the practice of medicine. Hematopoietic stem ... marrow transplants. Role of cells in drug discovery ...
(Date:5/28/2015)... SAN CARLOS, Calif. , May 28, 2015 ... genetic testing, today announced a study published in ... that the Panorama single-nucleotide polymorphism (SNP)-based non-invasive prenatal ... in the first trimester. A ... indicates that complete molar pregnancies occur in about ...
Breaking Biology Technology:Seoul Semiconductor Increases the Global Automotive LED Market Share with its High Efficient and Reliable LEDs for Automotive Lightings 2Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3
... , Introduction , ... , or probes in genetic analysis. Quality control ... by slab gel electrophoresis or HPLC, but these , ... not provide desired quantitative precision or automation. Capillary electrophorsis , ...
... Michiels 1 , Baudouin Franois 1, 2 , and Jef , ... Centrum, Universitaire Campus, B-3590 Diepenbeek, Belgium , ... , Phenylketonuria (PKU) is a hereditary disease ... phenylalanine. The disease most frequently is caused by , ...
... Shiell and Wojtek P. Michalski, CSIRO Division of Animal Health,Australian Animal Health Laboratory, Geelong, ... Introduction , ... performed , on samples derived from polyacrylamide ... used method of recovering proteins from gels, can be , ...
Cached Biology Technology:Oligonucleotide Purity Analysis by Capillary Electrophoresis 2Oligonucleotide Purity Analysis by Capillary Electrophoresis 3Identification of Disease Causing Mutations in Phenylketonuria by Denaturing Gradient Gel Electrophoresis Using the DCode System 2Identification of Disease Causing Mutations in Phenylketonuria by Denaturing Gradient Gel Electrophoresis Using the DCode System 3Identification of Disease Causing Mutations in Phenylketonuria by Denaturing Gradient Gel Electrophoresis Using the DCode System 4Identification of Disease Causing Mutations in Phenylketonuria by Denaturing Gradient Gel Electrophoresis Using the DCode System 5Fractionation of Bovicola ovis Homogenates Using the Mini Whole Gel Eluter 2Fractionation of Bovicola ovis Homogenates Using the Mini Whole Gel Eluter 3
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, reminds investors and media that  Mr. ...  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of nine ... Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/20/2015)... April 20, 2015 Huntington Memorial Hospital is ... implant a new miniaturized, wireless monitoring sensor to manage ... first and only FDA-approved heart failure monitoring device that ... used by physicians to manage heart failure. ... implanted in the pulmonary artery (PA) during a non-surgical ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... native fish in Australia,s Murray-Darling Basin may be linked ... This is just one of the findings from a ... back into the Murray-Darling system limit fish reproduction and ... Rob Rolls said the results, published in Freshwater ...
... disorder characterized by the breakdown of cognition processes and ... throughout history. Scientists believe that several genes are associated ... single gene causes the disease by itself. It is ... necessary for schizophrenia to develop and that epigenetic change ...
... weapons testing of the 1950s and ,60s, Lawrence Livermore ... human brain involved in memory makes new neurons well ... on human behavior and mental health. The study supports ... adult neurogenesis to the treatment of age-related cognitive disorders. ...
Cached Biology News:Weapons testing data determines brain makes new neurons into adulthood 2
Phospho- (Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb...
... clone 41D GenBank Accession Number ... clusterin purified from human serum Formulation: ... and 0.05% sodium azide Quality Assurance: ... HeLa cells or MCF-7 cell lysates. ...
Anti-MT3-MMP Membrane-Type Metalloproteinase-3; propeptide domain; rabbit host...
Rabbit polyclonal to Methionine Aminopeptidase 2 ( Abpromise for all tested applications). entrezGeneID: 10988 SwissProtID: P50579...
Biology Products: